Cell and Gene Therapy: The $3M Claim Your Stop-Loss Carrier Is Excluding

Your stop-loss policy might not cover a $3 million gene therapy claim, even if you think it does. Many contracts now exclude these conditions, cap them with sublimits, or laser the individual member. One approved therapy can reprice your entire renewal before you ever see it.

Does your stop-loss policy actually cover a multimillion-dollar gene therapy claim?

Maybe not. The claims are real, and your contract was likely written before they showed up.

According to the City of Overland Park Stop Loss Analysis using Sun Life data, 47 members in Sun Life's book had claims over $3 million in a single year. Ten had claims over $5 million. The largest single claim hit $12.7 million.

Your stop-loss contract was written before those numbers showed up. The question is whether it still covers them.

What do cell and gene therapies actually cost?

Most run $1 million or more, and several run far higher. These aren't hypotheticals. They're FDA-approved drugs landing on real employer plans right now.

The ICER/NEWDIGS white paper on gene therapy financing puts the range plainly. These treatments are often priced at $2 to $4 million each. That range now spans dozens of approved therapies, with more coming.

Casgevy, the sickle cell gene therapy, showed positive long-term durability data at the 2025 European Hematology Association Congress, per the USC Schaeffer Center. That durability reduces the clinical argument for exclusion. It also raises the pressure on employers to cover it.

How are stop-loss carriers responding to these claims?

They're pricing around the risk, and often excluding it outright. Carriers know exactly which conditions lead to a seven-figure claim.

That same ICER analysis catalogs the common carrier responses. They exclude known high-cost conditions, laser individual high-risk members with higher deductibles, or raise the stop-loss premium. Often it's some combination of all three.

Here's what that means for you. If an employee has sickle cell disease, hemophilia, or another condition tied to an approved gene therapy, your carrier already knows. They'll price that member out of your aggregate protection or exclude the category at renewal.

Sublimits are the other mechanism. A carrier might cap gene and cell therapy claims at $500,000 or $1 million, well below the actual treatment cost. You think you have coverage, but not for the full claim.

None of this is isolated. It's part of a hardening market that's pushing reinsurance and stop-loss rates up 15% in 2026.

Why does claims concentration make this worse?

Because a handful of members already drive most of your spending. A gene therapy claim lands on top of an already top-heavy plan.

According to EBRI Fast Facts 544, the top 1% of health plan claimants have median spending of $150,000 per person and average spending of $206,000. That 1% accounts for 29% of total plan spending. The top 5% accounts for 57%.

A single gene therapy claim doesn't just blow your specific deductible. It reshapes your entire renewal. Carriers see the history, price accordingly, and often laser or exclude before you reach the table.

That's why the strategy conversation has to happen before a claim hits. Not after.

What can self-funded employers actually do about it?

Three moves matter. Read your contract, look at carve-out programs, and spread the risk.

First, read your current stop-loss contract. Look for gene therapy exclusions, condition-specific sublimits, and "experimental" or "investigational" language. Approved FDA therapies aren't experimental, but some contracts still use that framing.

Second, look at carve-out or pooled programs built for cell and gene therapy. Cigna's Embarc Benefit Protection is one example, charging a modest per-member monthly premium with no cost-share for the treated member. Several carriers and reinsurers now offer gene therapy riders or separate pooling arrangements.

Third, consider a captive or consortium structure if your group is large enough. Spreading catastrophic risk across dozens of employers changes the math on any single claim. Some captives now build gene therapy coverage directly into their structure.

The worst move is assuming your current policy handles this because it handled everything else. It probably doesn't. Pull the contract, find the exclusions, and have the conversation before your next renewal.

Frequently asked questions

Are FDA-approved gene therapies considered experimental under stop-loss contracts?

They shouldn't be, but some contracts still carry "experimental" or "investigational" language that gets misapplied. FDA-approved therapies like Zynteglo and Skysona have cleared full regulatory review. Read your contract's definitions closely, because vague framing can trigger a coverage fight at claim time.

What is a gene therapy sublimit?

It's a cap your stop-loss carrier places on gene and cell therapy claims, often at $500,000 or $1 million. Many treatments cost $2 to $4 million, so the sublimit leaves you exposed for the difference. A sublimit is not the same as full coverage.

How much does a cell and gene therapy carve-out program cost?

Programs like Cigna's Embarc charge a modest per-member monthly premium, with no cost-share for the treated member. That's a small premium against a potential multimillion-dollar claim. Compare the per-member cost to your current exposure using our funding models guide before deciding.

Should we change our stop-loss attachment point because of gene therapy risk?

It depends on your claims history and cash flow, not on gene therapy alone. A single catastrophic claim can still exceed a low attachment point, so your exclusions and sublimits matter more than the specific deductible. Our guide on picking the right stop-loss attachment point walks through the tradeoffs.

What happens when a gene therapy prior authorization lands on our plan?

You'll need a fast, defensible coverage decision, because the claim can top $2 million. The plan document and your stop-loss terms drive whether you pay and how much you recover. Our breakdown of handling a $2 million prior auth covers the decision framework.